

wherein o is 0-6 and wherein the phenyl radical is optionally substituted up to twice, each substituent chosen independently from F, Cl, Br, OH, CF₃, NO₂, CN, OCF₃, (C₁-C₆)-alkoxy, (C₁-C₆)-alkyl, and NH₂; NH₂, NH-(C₁-C₆)-alkyl, N((C₁-C₆)-alkyl)₂, NH(C₁-C₇)-acyl, phenyl, or O-(CH₂)_o-phenyl,

wherein o is 0-6 and wherein the phenyl ring is optionally substituted one to 3 times, each substituent chosen independently from F, Cl, Br, I, OH, CF₃, NO₂, CN, OCF₃, (C₁-C₆)-alkoxy, (C₁-C₆)-alkyl, NH₂, NH(C₁-C₆)-alkyl, N((C₁-C₆)-alkyl)₂, SO₂-CH₃, COOH, COO-(C₁-C₆)-alkyl, and CONH₂;

A is (C₀-C₁₅)-alkanediyl, wherein one or more carbon atoms in the alkanediyl radical are optionally replaced, independently of one another, by -O-, -(C=O)-, -CH=CH-, -C≡C-, -S-, -CH(OH)-, -CHF-, -CF₂-, -(S=O)-, -(SO₂)-, -N((C₁-C₆)-alkyl)-, -N((C₁-C₆)-alkylphenyl)- or -NH-;

n is a number from 0 to 4;

Cyc1 is a 3- to 7-membered, saturated, partially saturated or unsaturated ring, wherein 1 carbon atom is optionally replaced by O or S;

R3, R4, R5 are, independently of each other, hydrogen, F, Cl, Br, I, OH, NO₂, CN, COOH, COO(C₁-C₆)-alkyl, CO(C₁-C₄)-alkyl, CONH₂,

CONH(C₁-C₆)-alkyl, CON[(C₁-C₆)-alkyl]₂, (C₁-C₈)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₁-C₁₂)-alkoxy, HO-(C₁-C₆)-alkyl, or (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl,

wherein one, more than one or all hydrogens in the alkyl and alkoxy radicals are optionally replaced by fluorine;

SO₂-NH₂, SO₂NH(C₁-C₆)-alkyl, SO₂N[(C₁-C₆)-alkyl]₂, S-(C₁-C₆)-alkyl, S-(CH₂)_o-phenyl, SO-(C₁-C₆)-alkyl, SO-(CH₂)_o-phenyl, SO₂-(C₁-C₆)-alkyl, or SO₂-(CH₂)_o-phenyl,

wherein o is 0-6 and wherein the phenyl radical is optionally substituted up to twice, each substituent chosen

independently from F, Cl, Br, OH, CF₃, NO₂, CN, OCF₃, (C₁-C₆)-alkoxy, (C₁-C₆)-alkyl, and NH₂;

NH₂, NH-(C₁-C₆)-alkyl, N((C₁-C₆)-alkyl)₂, NH(C₁-C₇)-acyl, phenyl, (CH₂)_o-phenyl, O-(CH₂)_o-phenyl,

wherein o is 0-6 and wherein the phenyl ring is optionally substituted one to 3 times, each substituent chosen

independently from F, Cl, Br, I, OH, CF₃, NO₂, CN, OCF₃,

(C₁-C₈)-alkoxy, (C₁-C₆)-alkyl, NH₂, NH(C₁-C₆)-alkyl,

N((C₁-C₆)-alkyl)₂, SO₂-CH₃, COOH, COO-(C₁-C₆)-alkyl, and CONH₂;

or

R3 and R4 together with the carbon atoms carrying them are a 5- to 7-membered, saturated, partially or completely unsaturated ring Cyc2,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

wherein 1 or 2 carbon atoms in the ring are optionally replaced by N, O or S, and

wherein Cyc2 is optionally substituted by (C₁-C₆)-alkyl, (C₂-C₅)-alkenyl, (C₂-C₅)-alkynyl,

wherein, in each substituent of Cyc2, one CH₂ group is optionally replaced by O, or substituted by H, F, Cl, OH, CF₃, NO₂, CN, COO(C₁-C₄)-alkyl, CONH₂, CONH(C₁-C₄)-alkyl, or OCF₃, and

R₅ is hydrogen;

or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1, wherein A is linked to the thienyl ring in position 2.
3. A compound as claimed in claim 1, wherein

R₁, R₂ are, independently of each other, hydrogen, F, Cl, Br, I, OH, NO₂, CN, COOH, CO(C₁-C₆)-alkyl, COO(C₁-C₆)-alkyl, CONH₂, CONH(C₁-C₆)-alkyl, CON[(C₁-C₆)-alkyl]₂, (C₁-C₈)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₁-C₆)-alkoxy, HO-(C₁-C₆)-alkyl, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl, phenyl, benzyl, (C₁-C₄)-alkylcarbonyl, or SO-(C₁-C₆)-alkyl,

wherein one, more than one or all hydrogens in the alkyl or alkoxy radicals are optionally replaced by fluorine;

- A is (C₀-C₁₅)-alkanediyl, wherein one or more carbon atoms in the alkanediyl radical are optionally replaced, independently of one another, by -O-, -(C=O)-, -CH=CH-, -C≡C-, -S-, -CH(OH)-, -CHF-, -CF₂-, -(S=O)-, -(SO₂)-, -N((C₁-C₆)-alkyl)-, -N((C₁-C₆)-alkylphenyl)- or -NH-;
- n is a number 2 or 3;
- Cyc1 is a 5- to 6-membered, saturated, partially saturated or unsaturated ring, wherein 1 carbon atom is optionally replaced by O or S;
- R3, R4, R5 are, independently of each other, hydrogen, F, Cl, Br, I, OH, NO₂, CN, COOH, COO(C₁-C₆)-alkyl, CO(C₁-C₄)-alkyl, CONH₂, CONH(C₁-C₆)-alkyl, CON[(C₁-C₆)-alkyl]₂, (C₁-C₈)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₁-C₁₂)-alkoxy, HO-(C₁-C₆)-alkyl, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl, (C₁-C₄)-alkylphenyl, (C₁-C₄)-alkoxyphenyl, S-(C₁-C₆)-alkyl, or SO-(C₁-C₆)-alkyl, wherein one, more than one or all hydrogens in the alkyl or alkoxy radicals are optionally replaced by fluorine;
- or
- R3 and R4 together with the carbon atoms carrying them are a 5- to 7-membered, saturated, partially or completely unsaturated ring Cyc2, wherein 1 or 2 carbon atoms in the ring are optionally replaced by N, O or S, and wherein Cyc2 is optionally substituted by (C₁-C₆)-alkyl, (C₂-C₅)-alkenyl, or (C₂-C₅)-alkynyl,

wherein in each substituent of Cyc2, one CH₂ group is optionally replaced by O, or substituted by H, F, Cl, OH, CF₃, NO₂, CN, COO(C₁-C₄)-alkyl, CONH₂, CONH(C₁-C₄)-alkyl, or OCF₃, and

R5 is hydrogen.

4. A compound as claimed in claim 1, wherein

R1, R2 are, independently of each other, hydrogen, (C₁-C₆)-alkyl, (C₁-C₄)-alkoxy, HO-(C₁-C₄)-alkyl, (C₁-C₄)-alkoxy-(C₁-C₄)-alkyl, F, Cl, CF₃, OCF₃, OCH₂CF₃ (C₁-C₄)-alkyl-CF₂-, phenyl, benzyl, (C₁-C₄)-alkylcarbonyl, (C₂-C₄)-alkenyl, (C₂-C₄)-alkynyl, or COO(C₁-C₄)-alkyl;

A is -CH=CH-CH₂- or (C₁-C₄)-alkanediyl, wherein one or two CH₂ groups are optionally replaced by - (C=O)-, -CH=CH-, -CH(OH)-, -NH-, -CHF-, -CF₂-, or -O-;

n is a number 2 or 3;

Cyc1 is unsaturated ring, wherein 1 carbon atom is optionally replaced by O or S;

R3, R4, R5 are, independently of each other, hydrogen, F, Cl, Br, I, NO₂, OH, CN, (C₁-C₆)-alkyl, (C₁-C₈)-alkoxy, OCF₃, OCH₂CF₃, S-(C₁-C₄)-

alkyl, COOH, HO-(C₁-C₄)-alkyl, (C₁-C₄)-alkoxy-(C₁-C₄)-alkyl, (C₁-C₂)-alkylphenyl, or (C₁-C₂)-alkoxyphenyl, or

R3 and R4 together are -CH=CH-O-, -CH=CH-S-, -O-(CH₂)_p-O-, -O-CF₂-O-, or -CH=CH-CH=CH-, wherein p = 1 or 2, and

R5 is hydrogen.

5. A compound as claimed in claim 1, wherein R2 is hydrogen.

6. A compound as claimed in claim 1, wherein

R1 is hydrogen, CF₃, (C₁-C₄)-alkyl, or phenyl,

R2 is hydrogen,

A is -CH₂-, -C₂H₄-, -C₃H₆-, -CH(OH)-, -(C=O)-, -CH=CH-, -CH=CH-CH₂-, -CO-CH₂-CH₂- or -CO-NH-CH₂-;

n is a number 2 or 3;

Cyc1 is unsaturated ring, wherein 1 carbon atom is optionally replaced by S;

R3,R4,R5 are, independently of each other, hydrogen, F, Cl, I, NO₂, OH, CN, (C₁-C₆)-alkyl, (C₁-C₈)-alkoxy, O-CH₂-phenyl, OCF₃, S-CH₃, or COOH or

R3 and R4 together are -CH=CH-O-, -O-(CH₂)_p-O-, -O-CF₂-O-, -CH=CH-CH=CH-, wherein p = 1 or 2, and

R5 is hydrogen.

7. A compound as claimed in claim 1, wherein
A is -CH₂- or -CH₂-CH₂-.
8. A compound as claimed in claim 1, wherein
Cyc1 is phenyl.
9. A compound as claimed in claim 1, wherein
Cyc1 is thienyl.
10. A compound as claimed in claim 1, wherein
Cyc1 is monosubstituted.
11. A medicament comprising at least one compound as claimed in claim 1.
12. A medicament comprising at least one compound as claimed in claim 1 and at least one more blood glucose-lowering active ingredient.
13. A method for treating type 1 or type 2 diabetes, comprising administering to a patient in need thereof an effective amount of at least one compound as claimed in claim 1.
14. A method for lowering blood glucose, comprising administering to a patient in need thereof an effective amount of at least one compound as claimed in claim 1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

15. A method for treating type 1 or type 2 diabetes, comprising administering to a patient in need thereof an effective amount of at least one compound as claimed in claim 1 and at least one other active ingredient, wherein the at least one other active ingredient is effective for lowering blood glucose.
16. A method for lowering blood glucose, comprising administering to a patient in need thereof an effective amount of at least one compound as claimed in claim 1 and at least one other active ingredient, wherein the at least one other active ingredient is effective for lowering blood glucose.
17. A process for producing a medicament comprising at least one compound as claimed in claim 1, comprising:
mixing the at least one compound as claimed in claim 1 with a pharmaceutically suitable carrier, and
converting this mixture into a form suitable for administration.